Compare FORTY & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORTY | KLRA |
|---|---|---|
| Founded | 1985 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 1998 | 2026 |
| Metric | FORTY | KLRA |
|---|---|---|
| Price | $117.51 | $17.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 406.0 | ★ 511.6K |
| Earning Date | 05-21-2026 | N/A |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $102.01 | $16.37 |
| 52 Week High | $190.56 | $23.82 |
| Indicator | FORTY | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 37.96 |
| Support Level | $115.00 | $16.39 |
| Resistance Level | $119.68 | $19.13 |
| Average True Range (ATR) | 0.45 | 0.97 |
| MACD | 1.61 | -0.06 |
| Stochastic Oscillator | 78.82 | 14.33 |
Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.